IMC Chicago’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$717K Buy
61,300
+6,800
+12% +$111K ﹤0.01% 4284
2026
Q2
$1.06M Sell
54,500
-14,600
-21% -$265K ﹤0.01% 3785
2026
Q1
$1.29M Buy
69,100
+1,600
+2% +$26.5K ﹤0.01% 3017
2025
Q4
$890K Buy
67,500
+13,100
+24% +$155K ﹤0.01% 3071
2025
Q3
$390K Buy
+54,400
New +$2.84M ﹤0.01% 3310

Other funds holding MLTX

IMC Chicago's MLTX Position: Q3 2026 in Review

IMC Chicago sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2026, closing a stake of 23,048 shares — an estimated $377K sold.

IMC Chicago first reported a position in MLTX in Q4 2025 and held it in 3 quarters. The position peaked at $481K in Q4 2025. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • IMC Chicago reported no remaining MoonLake Immunotherapeutics position as of Q3 2026 after selling out during the quarter.
  • IMC Chicago sold 23,048 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $377K.
  • IMC Chicago first reported a position in MoonLake Immunotherapeutics in Q4 2025 and held it in 3 quarters.
  • IMC Chicago's MoonLake Immunotherapeutics position peaked at $481K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.